| 1 |
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-55
DOI
ScienceOn
|
| 2 |
Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using singlephoton emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171-82
DOI
|
| 3 |
Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, et al. Positron emission tomographic imaging of the dopamine transporter with [ ]WIN35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34: 423-31
DOI
ScienceOn
|
| 4 |
Neuromeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, et al. N-w-Fluoroalkyl analogs of tropane$} "$2{\beta}-carbomethoxy- 3{\beta}-(4-iodophenyl)tropane$") ( ): radiotracers for PET and SPECT imaging of dopamine transporters. J Med Chem 1994; 37:1558-61
DOI
ScienceOn
|
| 5 |
Lundkvist C, Haldin C, Ginovart N, Swahn CG, Farde L.  is superior to 11C-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol 1997;24:621-7
DOI
ScienceOn
|
| 6 |
Guttman M, Burkholder J, Kish SJ, Hussev D, Wilson A, DaSilva J, et al. []RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48:1578-83
DOI
ScienceOn
|
| 7 |
Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using singlephoton emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171-82
DOI
|
| 8 |
Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [ ]-FP-CIT SPECT imaging: the [ ]-FP-CIT study group. Mov Disord 2000;15: 503-10
DOI
ScienceOn
|
| 9 |
O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-25
DOI
ScienceOn
|
| 10 |
Okada T, Fujita M, Shimada S, Sato K, Schloss P, Watanabe Y, et al. Assessment of affinities of beta-CIT, beta-CIT-FE, and beta-CIT-FP for monoamine transporters permanently expressed in cell lines. Nucl Med Biol 1998;25:53-8
DOI
ScienceOn
|
| 11 |
Scheffel U, Lever JR, Abraham P, Parham KR, Mathews WB, Kopajtic T, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse 1997;25:345-9
DOI
ScienceOn
|
| 12 |
Ritz MC, Cone EJ, Kuhar MJ. Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sci 1990;46:635-45
DOI
ScienceOn
|
| 13 |
Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, et al. Voxel-wise analysis of [ ]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 2005;128(Pt 7):1605-12
DOI
ScienceOn
|
| 14 |
Gatley SJ, Ding YS, Volkow ND, Chen R, Sugano Y, Fowler JS. Binding of d-threo-[]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine. Eur J Pharmacol 1995;281:141-9
DOI
ScienceOn
|
| 15 |
Madras BK, Meltzer PC, Liang AY, Elmaleh DR, Babich J, Fischman AJ. Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse 1998; 29: 93-104
DOI
ScienceOn
|
| 16 |
Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, et al. []PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 2003;30:1220-30
DOI
|
| 17 |
Ichise M, Toyama H, Innis RB, Carson RE. strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Metab 2002;22:1271-81
DOI
|
| 18 |
Laruelle M. The role of model-based methods in the development of single scan techniques. Nucl Med Biol 2000;27:637-42
DOI
ScienceOn
|
| 19 |
Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observerindependent evaluation of dopamine transporter SPECT studies. J Nucl Med 2005;46:1109-18
|
| 20 |
Booij J, Kemp P. Dopamine transporter imaging with [ ]FPCIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008;35:424-38
|
| 21 |
Gordon I, Weizman R, Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 1996;298:27-30
DOI
ScienceOn
|
| 22 |
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508
DOI
ScienceOn
|
| 23 |
Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, et al. Effect of treatment with L-dopa/carbidopa or Lselegiline on striatal dopamine transporter SPECT imaging with ![$^{[123}I]{\beta}-CIT$](http://ocean.kisti.re.kr/cgi-bin/mimetex.cgi?\small{$^{[123}I]{\beta}-CIT$} "$^{[123}I]{\beta}-CIT$") . Mov Disord 1999;14:436-42
DOI
ScienceOn
|
| 24 |
Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. ![$[^{123}I]{\beta}-CIT$](http://ocean.kisti.re.kr/cgi-bin/mimetex.cgi?\small{$[^{123}I]{\beta}-CIT$} "$[^{123}I]{\beta}-CIT$") SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:294-8
DOI
|
| 25 |
Fearnley J, Lees A. Aeging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301
DOI
ScienceOn
|
| 26 |
Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, et al. Imaging serotonin and dopamine transporters with  SPECT: Binding kinetics and effects of normal aging. J Nucl Med 2000;41:36-44
|
| 27 |
Mozley PD, Acton PD, Barraclough ED, Plossl K, Gur RC, Alavi A, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med 1999;40:1812-7
|
| 28 |
Leroy C, Comtat C, Trebossen R, Syrota A, Martinot J-L, Ribeiro M-J. Assessment of  Binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT. J Nucl Med
|
| 29 |
Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [![$N-^{11}C-methyl]-(-)- cocaine$](http://ocean.kisti.re.kr/cgi-bin/mimetex.cgi?\small{$N-^{11}C-methyl]-(-)- cocaine$} "$N-^{11}C-methyl]-(-)- cocaine$") PET studies in human subjects. J Cereb Blood Flow Metab 1990;10(5):740-7
DOI
|
| 30 |
Aquilonius SM, Bergstrom K, Eckernas SA, Hartviq P, Leenders KL, Lundquist H, et al. In vivo evaluation of striatal dopamine reuptake site  and positron emission tomography. Acta Neurol Scand 1987;76:283-7
DOI
ScienceOn
|
| 31 |
Rinne JO, Laihinen A, Nagren K, Ruottinen H, Ruotsalainen U, Rinne UK. PET examination of the monoamine transporter with [![$^{11}C]{\beta}-CIT$](http://ocean.kisti.re.kr/cgi-bin/mimetex.cgi?\small{$^{11}C]{\beta}-CIT$} "$^{11}C]{\beta}-CIT$") and [![$^{11}C]{\beta}-CFT$](http://ocean.kisti.re.kr/cgi-bin/mimetex.cgi?\small{$^{11}C]{\beta}-CFT$} "$^{11}C]{\beta}-CFT$") in early Parkinson's disease. Synapse 1995;21:97-103
DOI
ScienceOn
|
| 32 |
Ichise M, Meyer JH, Yonekura Y. An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 2001; 42:755-63
|
| 33 |
Slifstein M, Laruelle M. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med 2000;41: 2083-8
|
| 34 |
Vles JS, Feron FJ, Hendriksen JG, Jolles J, van Kroonenburgh MJ, Weber WE. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 2003;34:77-80
DOI
ScienceOn
|
| 35 |
Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, et al. Graphical, kinetic, and equilibrium analyses of in vivo ![$[^{123}I]{/beta}-CIT$](http://ocean.kisti.re.kr/cgi-bin/mimetex.cgi?\small{$[^{123}I]{/beta}-CIT$} "$[^{123}I]{/beta}-CIT$") binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1993;13:24-42
DOI
|
| 36 |
Lees AJ. Drugs for Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:607-10
DOI
ScienceOn
|
| 37 |
Yaqub M, Boellaard R, van Berckel BN, Ponsen MM, Lubberink M, Windhorst AD, et al. Quantification of dopamine transporter binding using [![$^{18}F]FP-b-CIT$](http://ocean.kisti.re.kr/cgi-bin/mimetex.cgi?\small{$^{18}F]FP-b-CIT$} "$^{18}F]FP-b-CIT$") and positron emission tomography. J Cereb Blood Flow Metab 2007;27:1397-406
DOI
ScienceOn
|
| 38 |
Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006;163:387-95
DOI
ScienceOn
|
| 39 |
Fowler JS, Volkow ND, Logan J, Franceschi D, Wang GJ, MacGregor R, et al. Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Life Sci 2001;68:2759-68
DOI
ScienceOn
|
| 40 |
Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, et al. Decreased single-photon emission computed tomographic []beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98
DOI
ScienceOn
|
| 41 |
Lavalaye J, Booij J, Reneman L, Habraken JBA, van Royen EA. Effect of age and gender on dopamine transporter imaging with ![$[^{123}I]FP-CIT$](http://ocean.kisti.re.kr/cgi-bin/mimetex.cgi?\small{$[^{123}I]FP-CIT$} "$[^{123}I]FP-CIT$") SPET in healthy volunteers. Eur J Nucl Med 2000; 27:867-9
DOI
|
| 42 |
Kas A, Payoux P, Habert MO, Malek Z, Cointepas Y, El Fakhri G, et al. Validation of a standardized normalization template for statistical parametric mapping analysis of  images. J Nucl Med 2007;48:1459-67
DOI
|
| 43 |
Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: A double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 2007;48: 359-66
|
| 44 |
Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-64
DOI
ScienceOn
|
| 45 |
Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991;9:43-9
DOI
ScienceOn
|
| 46 |
Niznik HB, Fogal EF, Fassos FF, Seaman P. The dopamine transporter is absent in Parkinsonian putamen and reduced in the caudate nucleus. Neurochem 1991;56:192-8
DOI
|
| 47 |
Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-23
DOI
ScienceOn
|
| 48 |
Neumeyer JL, Tamagnan G, Wang S, Gao Y, Milius RA, Kula NS, et al. N-substituted analogs of 2 beta-carbomethoxy-3 beta-(4'-iodophenyl)tropane (beta-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem 1996;39:543-8
DOI
ScienceOn
|
| 49 |
Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001;158:377-82
DOI
ScienceOn
|
| 50 |
Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 2005;32:1452-6
DOI
|
| 51 |
Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9-24
|
| 52 |
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratio without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-40
DOI
|
| 53 |
Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [ ]FPCIT SPECT. J Nucl Med 1999;40:753-61
|
| 54 |
Ma Y, Mentis DM, Chaly T, Spetsieris PG, Eidelberg D. Parametric mapping of [![^{18}F]FPCIT$](http://ocean.kisti.re.kr/cgi-bin/mimetex.cgi?\small{^{18}F]FPCIT$} "^{18}F]FPCIT$") binding in early stage Parkinson's disease: a PET study. Synapse 2002;45:125-33
DOI
ScienceOn
|
| 55 |
Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, Stark KF, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-6
DOI
ScienceOn
|
| 56 |
Seppi K, Scherfler C, Donnemiller E, Virgolini I, Schocke MF, Goebel G, et al. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise []beta-CIT SPECT analysis. Arch Neurol 2006;63(8):1154-60
DOI
ScienceOn
|
| 57 |
Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47: 1290-8
DOI
ScienceOn
|
| 58 |
Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Darqham A, Wallace E, et al. single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993;90:11965-9
DOI
ScienceOn
|
| 59 |
Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoqhbi SS, Baldwin RM, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of . J Nucl Med 1996;37:1129-33
|
| 60 |
Choi SR, Kung MP, Plossl K, Meegalla S, Kung HF. An improved kit formulation of a dopamine transporter imaging agent: [Tc-99m]TRODAT-1. Nucl Med Biol 1999;26:461-6
DOI
ScienceOn
|
| 61 |
Winogrodzka A, Booij J, Wolters ECh. Disease-related and drug induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease. Parkinsonism Relat Disord 2005; 11:475-84
DOI
ScienceOn
|
| 62 |
Bergstrom KA, Halldin C, Lundkvist C, Swahn CG, Akerman KK, Kuikka JT, et al. Characterization of C-11 or I-123 labelled  and  metabolism measured in monkey and human plasma. Identification of two labeled metabolites with HPLC. Hum Psychopharmacol 1996;11:483-90
|
| 63 |
Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand [ ]beta-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:737-41
DOI
|
| 64 |
Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med 1998;39:1521-30
|
| 65 |
Ma ST, Rinne JO, Collan Y, Roytta M, Rinne UK. A quantitative morpholmetrical study of neuron degeneration in the substantia nigra in Parkinson's disease. J neurol Sci 1996;140: 40-5
DOI
ScienceOn
|
| 66 |
Chou YH, Huang WS, Su TP, Lu RB, Wan FJ, Fu YK. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: a SPECT study. Eur Neuropsychopharmacol 2007;17:46-52
DOI
ScienceOn
|
| 67 |
Chaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, Dahl JR, et al. Radiosynthesis of [] $} "$N-3-fluoroporpyl-2-{beta}-carbomethoxy-3-{beta}-(4-iodophenyl)$") nortropane and the first human study with PET. Nucl Med Biol 1996;23:999-1004
DOI
ScienceOn
|
| 68 |
Kung HF, Kim HJ, Kung MP, Meegalla SK, Plossl K, Lee HK. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med 1996;23:1527-30
DOI
|
| 69 |
Kim DW, Ahn DS, Oh YH, Lee S, Kil HS, Oh SJ, et al. A new class of  reactions catalyzed by protic solvents: Facile fluorination for isotopic labeling of diagnostic molecules. J Am Chem Soc 2006;128:16394-7
DOI
ScienceOn
|
| 70 |
Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to []DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 2003;23:1096-112
DOI
|
| 71 |
Muller L, Halldin C, Farde L, Karlsson P, Hall H, Swahn CG, et al. [, a cocaine analog preparation autoradiography and preliminary PET investigations. Nucl Med Biol 1993;20: 249-55
DOI
ScienceOn
|
| 72 |
Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, et al. SPECT imaging of dopamine and serotonin transporters with : pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309
DOI
ScienceOn
|
| 73 |
Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [ ]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62: 133-40
DOI
ScienceOn
|
| 74 |
Telang FW, Volkow ND, Levy A, Logan J, Fowler JS, Felder C, et al. Distribution of tracer levels of cocaine in the human brain as assessed with averaged [] cocaine images. Synapse 1999;31(4):290-6
DOI
ScienceOn
|
webmaster
